What is the price target for HYL stock?
7 analysts have analysed HYL.BR and the average price target is 13.84 EUR. This implies a price increase of 131.4% is expected in the next year compared to the current price of 5.98.
HYLORIS PHARMACEUTICALS SA (HYL.BR) Forecast, Price Target & Analyst Ratings
EBR:HYL • BE0974363955
Current stock price
5.98 EUR
-0.02 (-0.33%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HYLORIS PHARMACEUTICALS SA (HYL.BR).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
€13.84
Upside
+ 131.41%
From current price of €5.98 to mean target of €13.84, Based on 7 analyst forecasts
Low
€6.06
Median
€14.59
High
€21.42
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for HYL.BR. The average price target is 13.84 EUR. This implies a price increase of 131.4% is expected in the next year compared to the current price of 5.98.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
HYL.BR was analyzed by 7 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about HYL.BR.
In the previous month the buy percentage consensus was at a similar level.
HYL.BR was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-12-22 | KBC SECURITIES | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 26, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 900K -70.93% | 2.087M 131.89% | 8.458M 305.27% | 16.791M 98.52% | 37.623M 124.07% | 78.805M 109.46% | |
| EBITDA YoY % growth | -11.312M -11.01% | -15.497M -37.00% | -5.721M 63.08% | -2.247M 60.72% | 8.787M 491.01% | 37.825M 330.47% | |
| EBIT YoY % growth | -11.508M -11.44% | -15.846M -37.70% | -6.369M 59.81% | -4.772M 25.07% | 7.979M 267.20% | 36.941M 362.98% | |
| Operating Margin | -1,278.67% | -759.27% | -75.30% | -28.42% | 21.21% | 46.88% | |
| EPS YoY % growth | N/A -2.27% | N/A -26.67% | N/A 2.34% | -0.35 38.32% | -0.16 54.37% | 0.58 468.08% |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
44.80%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
102.83%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
72.96%
EBIT Next 5 Year
N/A
HYLORIS PHARMACEUTICALS SA / HYL.BR Forecast FAQ
When does HYLORIS PHARMACEUTICALS SA (HYL.BR) report earnings?
HYLORIS PHARMACEUTICALS SA (HYL.BR) will report earnings on 2026-03-26, after the market close.
What is the consensus rating for HYL stock?
The consensus rating for HYLORIS PHARMACEUTICALS SA (HYL.BR) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.